Pavel Ryzhov, PhD’s Post

Partner with WuXi Biologics for your bsAb project, from discovering optimal pairings to scalable production with high purity across formats. Learn more: https://hubs.li/Q02SwHLR0

Are you headed to Antibody Therapeutics Xchange in San Franscico on Monday, September 23? Want to discuss opportunities with our Business Development team? Reach out to schedule a time! We’re looking forward to engaging discussions with leaders in the early stages of biologics research and supporting your 2024 R&D goals. Schedule a Meeting in Advance: ▶️https://lnkd.in/eAg4H58n #AntibodyTherapeutics #hubXchange #WuXiBiologics #DrugDiscovery #AntibodyDiscovery

Do this!!!

Antibody silencing - did we Fc it up? Since the 90s antibody researchers have primarily selected effector null Fc domains based simply on which variants have been used in the clinic. Frustratingly new variants are rarely compared with each other and all claim to be 'silent'. For the first time we now have a full comparison! A few years ago Geoff Hale and I analysed over 800 INNs and described their structural design and Fc mutations. To our surprise we found about 50 mutations that had been used for the purpose of Fc silencing (i.e. elimination of effector function) and we promised to follow up with a publication comparing them. It might have taken us 2 years but we did go a step further and looked at >70 silent variants in a wide range of assays (SPR, cell based, FcgR affinity chromatography and stability). This was in part because we were fed up of people asking "have you compared mAbsolve's STR with XYZ". We believe we have now tested every silencing variant that has ever been in the clinic and any that have been cited in the literature on multiple occasions. As you might expect, there are substantial differences between the variants. Some are so far from being silent it is worrying. Others are very good but fortunately for us STR still comes out on top. Our board had serious reservations on starting this project due to the risks of undermining STR but Geoff and I felt that it would be far better to have truly comparative data out in the open whatever the outcome. Now for the first time ever researchers across the world can get a clear view of how the mutations they are using compare to others, or for those new to Fc silencing it can help steer people towards a choice driven by scientific data rather than simply what has gone before (e.g. IgG4). The paper is open access and all the data can be downloaded in an Excel sheet in the supplementary data. DOI: https://lnkd.in/ejgedUNs Did we miss any mutations? Let me know in the comments! If you are interested in discussing licensing of the STR mutations drop me a message or contact us through mabsolve.com. And we didn't stop there. We've also been comparing most of the Fc enhancing mutations. That paper is in review and will hopefully be out soon. Thanks to our collaborators at Protein Stable (Alastair Davy) and RIC group (Jelle De Vos), and to Janice Reichart, mAbs and The Antibody Society for their continued support in our efforts to provide robust, reliable and publicly available data to enable data driven selection of optimal Fc variants. ----- I'm Ian, I post about antibody engineering, recombinant proteins and my journey to bootstrap Gamma Proteins into a leading supplier of Fc receptors. If you like my content please follow me to see more.

Polaris Dawn is NOT space tourism   Yesterday at 9:23 AM UTC, the SpaceX Polaris Dawn mission launched aboard a Crew Dragon. Once again, media in the German-speaking world are reporting about Polaris Dawn as "space tourism." Polaris Dawn is not space tourism. Space tourists have no crew duties. This crew has significant duties, and I have enormous respect for that. 🌎On the Polaris Dawn mission, the next generation of space suits for extravehicular activities is being tested. These suits have been developed by SpaceX over several years. Why? Traditional space suits do not meet the requirements for mass production. Mass production of space suits is a necessary milestone on the path to industrialized space flight. 🌎The mission will test laser communication methods in space, essential for building efficient and fast communication networks in space. 🌎Furthermore, 38 scientific experiments from 23 research institutions worldwide will be conducted, focusing on medical research and testing new medical devices. Due to Polaris Dawn’s unique mission profile—a highly elliptical orbit reaching up to 1'400 kilometers from the Earth's surface - astronauts and spacecraft will be exposed to high radiation levels from the Van Allen Belt, providing valuable data for future missions into deeper space. 🌎The Polaris Dawn mission is flown by a highly professional crew of two women and two men: Sarah Gillis, SpaceX Chief Engineer and Head of the Astronaut Training Program, Anna Menon, Engineer and SpaceX Mission Director, Scott Poteet, Air Force Test Pilot and SpaceX Mission Director, and Jared Isaacman, a passionate pilot and philanthropist who has already been in space with the Inspiration4 mission. This is a mission of experienced and trained private astronauts testing new and essential space technology while taking on exceptionally high personal risks. Private spaceflight will provide humanity with unprecedented access to low Earth orbit. The next era of space flight has already begun. (picture credit: Space X on "X")